Dinara Ryspayeva - National Cancer Institute

M. Maglakelidze,D. Ryspayeva, Z.G. Andric, Z. Petrovic, I.V. Bulat, I.V. Nikolic, T. Chawla, R. Nagarkar,U. Wiedermann, B.A. Blumenstein, L.M.O. Chong, N.J. Ede,

Annals of Oncology (2022): S1460-S1460

引用0浏览0引用

Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter

Dinara Ryspayeva,Volodymyr Halytskiy,Nazarii Kobyliak,Iryna Dosenko,Artem Fedosov,Mariia Inomistova,Tetyana Drevytska,Vitalyi Gurianov,Oksana Sulaieva

Discov Onc（2022）

引用3浏览0WOS引用

HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

Rita Laeufle,Marina Maglakelidze,Iurie Bulat,Dinara Ryspayeva,Andric Zoran,Tanuj Chawla,Ivan Nikolic,Rajnish Nagarkar,Giri Venkata,Vaibhav Choudhary,Davorin Radosavljevic,Rajesh Kumar Singh,

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用1浏览0引用

Optimal integration of CDK4/6 inhibitors for treatment of hormone receptor-positive metastatic breast cancer

D.Ye. Ryspayeva

Practical oncologyno. 1 (2021): 11-18

引用0浏览0引用

A Phase 1b/2 Open-Label Study With Randomization In Phase 2 Of Imu-131 Her2/Neu Peptide Vaccine Plus Standard Of Care Chemotherapy In Patients With Her2/Neu Overexpressing Metastatic Or Advanced Adenocarcinoma Of The Stomach Or Gastroesophageal Junction

Marina Maglakelidze,Dinara Ryspayeva,Iurie Bulat,Zoran Andric,Ivan Nikolic,Tanuj Chawla, Rajnish Nagarkar,Vaibhav Chourdhary,Giri Venkata,Rajesh Kumar Singh,Davorin Radosavljevic,Zoran Petrovic,

CANCER RESEARCH（2021）

引用3浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn